About Company
Founded in 2008 through the merger of Tripos International and Pharsight Corporation, Certara specializes in model-informed drug development (MIDD). The company leverages advanced biosimulation technology to enhance decision-making in drug discovery and development, helping pharmaceutical and biotechnology companies optimize their research and development processes. Certara's services encompass various therapeutic areas, including immuno-oncology, rare diseases, and gene therapy, providing integrated solutions from early-stage discovery to regulatory submission.